BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lankes K, Hassan Z, Doffo MJ, Schneeweis C, Lier S, Öllinger R, Rad R, Krämer OH, Keller U, Saur D, Reichert M, Schneider G, Wirth M. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. Mol Oncol 2020;14:3048-64. [PMID: 33099868 DOI: 10.1002/1878-0261.12835] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Schneeweis C, Diersch S, Hassan Z, Krauß L, Schneider C, Lucarelli D, Falcomatà C, Steiger K, Öllinger R, Krämer OH, Arlt A, Grade M, Schmidt-Supprian M, Hessmann E, Wirth M, Rad R, Reichert M, Saur D, Schneider G. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. Cell Mol Life Sci 2022;80:12. [PMID: 36534167 DOI: 10.1007/s00018-022-04638-y] [Reference Citation Analysis]
2 Schneeweis C, Hassan Z, Ascherl K, Wirth M, Koutsouli S, Orben F, Krauß L, Schneider C, Öllinger R, Krämer OH, Rad R, Reichert M, Robles MS, Saur D, Schneider G. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Cancer Commun (Lond) 2022. [PMID: 35253411 DOI: 10.1002/cac2.12280] [Reference Citation Analysis]
3 Doffo J, Bamopoulos SA, Köse H, Orben F, Zang C, Pons M, den Dekker AT, Brouwer RWW, Baluapuri A, Habringer S, Reichert M, Illendula A, Krämer OH, Schick M, Wolf E, van IJcken WFJ, Esposito I, Keller U, Schneider G, Wirth M. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Proc Natl Acad Sci U S A 2022;119:e2105691119. [PMID: 35197278 DOI: 10.1073/pnas.2105691119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Wirth M. Targeting the translational machinery to overcome apoptosis resistance in pancreatic cancer. Transl Oncol 2022;17:101343. [PMID: 35078019 DOI: 10.1016/j.tranon.2022.101343] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Murugan NJ, Voutsadakis IA. Proteasome regulators in pancreatic cancer. World J Gastrointest Oncol 2022; 14(1): 38-54 [DOI: 10.4251/wjgo.v14.i1.38] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Doffo J, Bamopoulos SA, Köse H, Orben F, Zang C, Pons M, den Dekker AT, Brouwer RWW, Baluapuri A, Habringer S, Reichert M, lllendula A, Krämer OH, Schick M, Wolf E, van Ijcken WFJ, Esposito I, Keller U, Schneider G, Wirth M. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer.. [DOI: 10.1101/2021.10.21.465266] [Reference Citation Analysis]
7 Schneider G, Wirth M, Keller U, Saur D. Rationale for MYC imaging and targeting in pancreatic cancer. EJNMMI Res 2021;11:104. [PMID: 34637026 DOI: 10.1186/s13550-021-00843-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Voutsadakis IA. Mutations of p53 associated with pancreatic cancer and therapeutic implications. Ann Hepatobiliary Pancreat Surg 2021;25:315-27. [PMID: 34402431 DOI: 10.14701/ahbps.2021.25.3.315] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wirth M, Schick M, Keller U, Krönke J. Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy. Cancers (Basel) 2020;12:E3764. [PMID: 33327527 DOI: 10.3390/cancers12123764] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]